Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help...

Full description

Bibliographic Details
Main Authors: Pengfei Jin, Jingxin Li, Hongxing Pan, Yanfei Wu, Fengcai Zhu
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00481-y
Description
Summary:Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.
ISSN:2059-3635

Similar Items